Expression and function of microRNA‑27b in hepatocellular carcinoma

He,Shujie; Zhang,Jingyuan; Lin,Juan; Zhang,Cuisheng; Sun,Shijie

doi:10.3892/mmr.2016.4851

Expression and function of microRNA‑27b in hepatocellular carcinoma

Authors:
- Shujie He
- Jingyuan Zhang
- Juan Lin
- Cuisheng Zhang
- Shijie Sun
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Yantai Mountain Hospital, Yantai, Shandong 264001, P.R. China, Department of Medical Administration, Yuhuangding Hospital, Yantai, Shandong 264001, P.R. China, Department of Internal Medicine, Government Hospital of Yantai, Yantai, Shandong 264001, P.R. China, Department of Hepatobiliary Surgery, Yuhuangding Hospital, Yantai, Shandong 264001, P.R. China
Published online on: February 3, 2016 https://doi.org/10.3892/mmr.2016.4851
Pages: 2801-2808

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been reported that microRNAs (miRs) have key roles in tumorigenesis via inhibition of their target genes. Dysregulation of miR‑27b has been detected in numerous types of human cancer, including hepatocellular carcinoma (HCC); however, the detailed role of miR‑27b in HCC has yet to be elucidated. Reverse transcription‑quantitative polymerase chain reaction and western blotting were performed to examine the mRNA and protein expression levels. Transwell assay and wound healing assay were used to determine cell invasion and migration. Luciferase reporter assay was to confirm the targeting relationship. The present study demonstrated that the expression levels of miR‑27b were significantly increased in HCC cell lines, as compared with in normal human liver cells. In addition, miR‑27b was frequently upregulated in HCC tissues, as compared with in normal adjacent tissues; the expression levels of miR‑27b were increased in 77.1% (27/35) of the HCC tissue samples. Furthermore, elevated miR‑27b expression levels were significantly correlated with tumor differentiation, Tumor Node Metastasis stage and vascular invasion (P<0.05). Knockdown of miR‑27b expression inhibited HCC cell migration and invasion. Furthermore, Sprouty 2 (Spry2) was identified as a novel target of miR‑27b in HCC HepG2 cells, and the protein expression levels of Spry2 were negatively regulated by miR‑27b in HepG2 cells. Overexpression of Spry2 suppressed HCC cell migration and invasion, whereas downregulation of Spry2 reversed the suppressive effects of miR‑27b inhibition on HCC cell migration and invasion. The results of the present study suggested that miR‑27b may promote the migration and invasion of HCC cells, at least partially by suppressing Spry2 expression. Therefore, the miR‑27b/Spry2 axis may be considered a potential therapeutic target for HCC.

View Figures

View References

1	Zhu AX: Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: Current status and future perspectives. Semin Oncol. 39:493–502. 2012. View Article : Google Scholar : PubMed/NCBI
2	Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V and Dimitriadis G: Pathways and targets in hepatocellular carcinoma. Expert Rev Anticancer Ther. 12:1347–1357. 2012. View Article : Google Scholar : PubMed/NCBI
3	Li P, Tao L, Yang J, Cai H, Ju X, Li J, Shao P, Cao Q, Qin C, Meng X and Yin C: Sprouty2 is associated with prognosis and suppresses cell proliferation and invasion in renal cell carcinoma. Urology. 82:253e1–e7. 2013. View Article : Google Scholar : PubMed/NCBI
4	Mei Y, Bian C, Li J, Du Z, Zhou H, Yang Z and Zhao RC: miR-21 modulates the ERK-MAPK signaling pathway by regulating SPRY2 expression during human mesenchymal stem cell differentiation. J Cell Biochem. 114:1374–1384. 2013. View Article : Google Scholar
5	Song K, Gao Q, Zhou J, Qiu SJ, Huang XW, Wang XY and Fan J: Prognostic significance and clinical relevance of Sprouty 2 protein expression in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 11:177–184. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
9	Coulouarn C, Factor VM, Andersen JB, Durkin ME and Thorgeirsson SS: Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 28:3526–3536. 2009. View Article : Google Scholar : PubMed/NCBI
10	Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar
11	Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT: MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012. View Article : Google Scholar : PubMed/NCBI
12	Yin W, Zhao Y, Ji YJ, Tong LP, Liu Y, He SX and Wang AQ: Serum/plasma microRNAs as biomarkers for HBV-related hepatocellular carcinoma in China. Biomed Res Int. 2015:9651852015. View Article : Google Scholar : PubMed/NCBI
13	Zhuo L, Liu J, Wang B, Gao M and Huang A: Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep. 29:555–562. 2013.
14	Valencia-Quintana R, Sánchez-Alarcón J, Tenorio-Arvide MG, Deng Y, Montiel-González JM, Gómez-Arroyo S, Villalobos-Pietrini R, Cortés-Eslava J, Flores-Márquez AR and Arenas-Huertero F: The microRNAs as potential biomarkers for predicting the onset of aflatoxin exposure in human beings: A review. Front Microbiol. 5:1022014. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
16	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
17	Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu C, Zou L, Li Z, Zhao J and Lin N: MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett. 586:4362–4370. 2012. View Article : Google Scholar : PubMed/NCBI
18	Heo MJ, Kim YM, Koo JH, Yang YM, An J, Lee SK, Lee SJ, Kim KM, Park JW and Kim SG: microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. Oncotarget. 5:2792–2806. 2014. View Article : Google Scholar : PubMed/NCBI
19	Her GM, Hsu CC, Hong JR, Lai CY, Hsu MC, Pang HW, Chan SK and Pai WY: Overexpression of gankyrin induces liver steatosis in zebrafish (Danio rerio). Biochim Biophys Acta. 1811:536–548. 2011. View Article : Google Scholar : PubMed/NCBI
20	Ishteiwy RA, Ward TM, Dykxhoorn DM and Burnstein KL: The microRNA −23b/−27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. PLoS One. 7:e521062012. View Article : Google Scholar
21	Wan L, Zhang L, Fan K and Wang J: MiR-27b targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol Cell Biochem. 390:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
22	Lee JJ, Drakaki A, Iliopoulos D and Struhl K: MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene. 31:3818–3825. 2012. View Article : Google Scholar :
23	Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA and Alahari SK: Prooncogenic factors miR-23b- and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer. Cancer Res. 73:2884–2896. 2013. View Article : Google Scholar : PubMed/NCBI
24	Chen L, Li H, Han L, Zhang K, Wang G, Wang Y, Liu Y, Zheng Y, Jiang T, Pu P, et al: Expression and function of miR-27b in human glioma. Oncol Rep. 26:1617–1621. 2011.PubMed/NCBI
25	Yoshitaka T, Kawai A, Miyaki S, Numoto K, Kikuta K, Ozaki T, Lotz M and Asahara H: Analysis of microRNAs expressions in chondrosarcoma. J Orthop Res. 31:1992–1998. 2013. View Article : Google Scholar : PubMed/NCBI
26	Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J and Chen X: Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology. 47:1200–1210. 2008. View Article : Google Scholar : PubMed/NCBI
27	Wang C, Delogu S, Ho C, Lee SA, Gui B, Jiang L, Ladu S, Cigliano A, Dombrowski F, Evert M, et al: Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. J Hepatol. 57:577–583. 2012. View Article : Google Scholar : PubMed/NCBI